These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28294737)

  • 1. [Trimetazidine in the Treatment of Chronic HeartFailure].
    Zhirov IV; Osmolovskaya YF; Tereshchenko SN
    Kardiologiia; 2016 Jan; 56(1):79-85. PubMed ID: 28294737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine and cardioprotection: facts and perspectives.
    Tsioufis K; Andrikopoulos G; Manolis A
    Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D; Ning N; Niu X; Hao G; Meng Z
    Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine: the future of cardiac function?
    Di Napoli P; Taccardi AA
    Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis.
    Jackson G
    Int J Clin Pract; 2006 Aug; 60(8):891-2. PubMed ID: 16893429
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of trimetazidine on heart rate variability in patients with heart failure.
    Gunes Y; Guntekin U; Tuncer M; Sahin M
    Arq Bras Cardiol; 2009 Aug; 93(2):154-8. PubMed ID: 19838493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H; Neubauer S
    Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic therapy for heart failure.
    Essop MF; Opie LH
    Eur Heart J; 2004 Oct; 25(20):1765-8. PubMed ID: 15474689
    [No Abstract]   [Full Text] [Related]  

  • 10. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
    O'Meara E; McMurray JJ
    Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure].
    Gorbunova ML; Vilkova AV
    Kardiologiia; 2016 Mar; 56(3):67-72. PubMed ID: 28294892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study.
    Fragasso G; Rosano G; Baek SH; Sisakian H; Di Napoli P; Alberti L; Calori G; Kang SM; Sahakyan L; Sanosyan A; Vitale C; Marazzi G; Margonato A; Belardinelli R
    Int J Cardiol; 2013 Mar; 163(3):320-325. PubMed ID: 23073279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease].
    Nedoshivin AO; Kutuzova AE; Nesterova IV; Mikhaĭlova IE; Rubashkina EI; Novikova NA; Liasnikova EA; Perepech NB
    Kardiologiia; 2002; 42(3):12-5. PubMed ID: 12494179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Possibilities of myocardial cytoprotection in complex treatment of patients with chronic heart failure].
    Vasiuk IuA; Iushchuk EN; Shkol'nik EL; Khadzegova AB; Vit'ko NK; Vakhromeeva MN
    Kardiologiia; 2006; 46(11):48-56. PubMed ID: 17159882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure].
    Sedova EM; Magnitskaia OV
    Kardiologiia; 2010; 50(1):62-3. PubMed ID: 20144159
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of trimetazidine in nonischemic heart failure: a randomized study.
    Winter JL; Castro PF; Quintana JC; Altamirano R; Enriquez A; Verdejo HE; Jalil JE; Mellado R; Concepción R; Sepúlveda P; Rossel V; Sepúlveda L; Chiong M; García L; Lavandero S
    J Card Fail; 2014 Mar; 20(3):149-54. PubMed ID: 24412523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.
    Lopatin YM; Rosano GM; Fragasso G; Lopaschuk GD; Seferovic PM; Gowdak LH; Vinereanu D; Hamid MA; Jourdain P; Ponikowski P
    Int J Cardiol; 2016 Jan; 203():909-15. PubMed ID: 26618252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure.
    Thrainsdottir IS; von Bibra H; Malmberg K; Rydén L
    J Cardiovasc Pharmacol; 2004 Jul; 44(1):101-8. PubMed ID: 15175564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ; Mishra S
    Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.